Knowledge Matrix Secures Over RMB 10 Million in Series A3 Funding to Accelerate Expansion in the Health Ecosystem

Major Move Emerges Again in the Primary Market for Full-Chain Ecosystem Operations in the Healthcare and Wellness Sector.

On December 25, 2024, KNOTRIX officially announced the completion of its tens-of-millions RMB Series A2 financing round, aiming to further advance its content ecosystem development and commercial strategic layout in the big health sector. Just one month later, KNOTRIX announced again that it had secured over ten million RMB in its Series A3 financing round.

This round of financing was led by Cofoe Medical, with the proceeds allocated to supply chain expansion, R&D investment, and brand building. This marks the full completion of KNOTRIX’s Series A financing. Concurrently, both parties signed a Strategic Cooperation Agreement to engage in deep collaboration across industry research, brand marketing, market expansion, and industrial cooperation, jointly promoting the development of the medical device industry and achieving mutual benefits and win-win outcomes.

It is reported that Cofoe Medical is one of the leading enterprises in China’s home medical device industry. With over two decades of deep engagement in the sector, its main product portfolio covers five major areas: health monitoring, rehabilitation aids, respiratory support, medical nursing, and traditional Chinese medicine physiotherapy. The company has evolved into a highly competitive and influential player in the industry, characterized by a comprehensive product range, well-established distribution channels, and advanced technology. Since 2015, Cofoe Medical has consistently maintained a leading position in online sales. The “Cofoe” brand ranks among the top in transaction indices for medical devices on both Tmall and JD.com platforms, having cumulatively provided diversified products and services to 50 million households worldwide.

Zhang Min, Chairman of Cofoe Medical, stated: “This strategic cooperation with KNOTRIX is a significant strategic initiative for the company in terms of brand building and market expansion. Both parties will fully leverage their resource and professional advantages to break through traditional industry boundaries and bring more innovative products and services to the medical device industry.”

A review of KNOTRIX’s financing history reveals that it is a company highly favored by investors. This preference is closely tied to the heightened attention the industry has garnered. In recent years, full-spectrum ecosystem operations for pharmaceuticals and medical devices have gained significant prominence. As enterprises and capital continue to increase their investments, the market size is also experiencing rapid growth.

However, pharmaceutical and medical device companies are simultaneously raising their requirements for partners, while tighter regulations are imposing stricter compliance standards on these enterprises. As a result, the industry is undergoing a significant reshuffle. Nevertheless, against this challenging backdrop, KNOTRIX has not only seen rapid expansion in its business scale but also received frequent positive news from the capital market. We learned the reasons behind this success from Ding Zhaoliang (Danggui), Founder and CEO of KNOTRIX.

One of KNOTRIX’s core competitive advantages lies in its ability to meet the demand of pharmaceutical, medical device, and broader health industry enterprises for one-stop, full-chain ecosystem operation services. In other words,KNOTRIX possesses the capability to provide “one-stop” services, encompassing comprehensive content across pharmaceuticals, medical devices, and general health products, along with a big data ecosystem.

Concretizing “one-stop” service capabilities entails two primary dimensions: first, content production and account coverage capabilities; second, the ability to support precise marketing decisions and business strategic decisions based on process management and big data analytics.

In terms of content production and account coverage, KNOTRIX has achieved economies of scale. Its annual total content views across all platforms exceed 30 billion, with over 70,000 original medical content pieces produced annually and more than 520 videos garnering over 10 million views each year. Currently, KNOTRIX has independently incubated over 200 health and wellness IPs and partnered with more than 3,000 health and wellness IPs. The combined follower count for its proprietary IPs across all platforms has surpassed 130 million, while the combined follower count for its partnered health and wellness IPs has exceeded 430 million.

It is worth noting that the massive production of professional health-related content by KNOTRIX is underpinned by large language model capabilities. According to KNOTRIX, leveraging its proprietary CHEESE CAKE high-quality copywriting and script generation system, the company has achieved an annual output capacity of 3 million words for copywriting, a daily tracking capacity of 50,000 words for product reviews, and a daily service capacity of 13,000 words for fan engagement, significantly enhancing the efficiency of high-quality copywriting and script generation.

andIn terms of precision marketing decision-making capabilities, KNOTRIX has also independently developed the K6 Precision Marketing Model.Ding Zhaoliang (Danggui) revealed in the interview that currently,The K6 Precision Marketing Model enables granular analysis of key nodes in the pharmaceutical marketing value chain.“Previously, the digital marketing funnel in the pharmaceutical industry suffered from a ‘black box’ problem, making it impossible to identify which specific ‘elements’ ‘resonated’ with consumer groups. Now, empowered by the K6 model, we can identify these key elements and refine them in a targeted manner to enhance marketing precision,” said Ding Zhaoliang (Danggui).

KNOTRIX K6 Precision Marketing Model

Meanwhile, Ding Zhaoliang (Danggui) also revealed that KNOTRIX is currently integrating resources from pharmaceutical companies, academic institutions, and strategic partnership platforms under strict compliance requirements to develop a big data support model for commercial strategic decision-making. Leveraging multi-dimensional data—including 50 million precise user direct messages generated by high-quality video content, 200 million effective feedback instances from live streaming sessions, 100 million cross-platform keyword searches, and 500 million new product impressions—KNOTRIX deeply mines the pain points and consumption behavior trends of segmented populations. By analyzing network-wide user opinions and behavioral insights, it provides customized commercial strategic decision-making support to its partners.

KNOTRIX Business Strategic Decision Big Data Support Model

It is not difficult to see that,Two key elements underpin KNOTRIX’s provision of one-stop, end-to-end ecosystem services: content and the power of big data.In fact, during the interview, when VCBeat asked about the core competitiveness of KNOTRIX, Ding Zhaoliang (Danggui) responded first by stating, “We are a company that holds data and scientific technology in the highest regard. We do not place blind faith in content, nor do we uncritically embrace technology. Only when data and technology resonate with each other do we truly possess the capacity for scalable content innovation.”

Likewise,When mass content creation capabilities meet end-to-end, one-stop ecosystem services, KNOTRIX gains what Ding Zhaoliang (Danggui) calls its third advantage: economies of scale.Serving over 100 pharmaceutical and medical device companies, partnering with more than 1,000 consumer brands, and driving over RMB 1 billion in GMV growth for pharmaceutical enterprises—such is KNOTRIX’s current track record. We look forward with great anticipation to its future development.